AstraZeneca Fourth Quarter and Full-Year 2011 Results - Interviews

LONDON, February 2, 2012 /PRNewswire/ --

AstraZeneca, the Anglo-Swedish pharmaceutical company, said that government price intervention had reduced its revenues by about $1bn as it announced further restructuring alongside its full-year results.

In an interview on, David Brennan, CEO, discusses AstraZeneca's portfolio performance including Brilinta and Crestor, and the prospects for the  pipeline in light of recent disappointments.

He also reaffirms his strong commitment to returning cash to shareholders. 

Also interviewed about the rationale behind the latest phase of the restructuring, Martin Mackay, President, R&D, said:

"We have to be a very flexible organisation to make sure that we're dynamic enough to work in the environment that we work in but also produce great medicines."

Tony Zook, EVP, Global Commercial, also talks about his confidence in AstraZeneca's ability to deliver top line performance and the importance of emerging markets for future growth. 

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.

SOURCE AstraZeneca

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.